Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blinded, Placebo-controlled, Prospective, Multicenter Trial to Evaluate the Efficacy and Safety of SC Immunotherapy in Patients With Rhinitis With Mild to Moderate Asthma Sensitized to D.Pteronyssinus and/or D.Farinae

Next Previous
Search
Trial Profile

A Randomized, Double-blinded, Placebo-controlled, Prospective, Multicenter Trial to Evaluate the Efficacy and Safety of SC Immunotherapy in Patients With Rhinitis With Mild to Moderate Asthma Sensitized to D.Pteronyssinus and/or D.Farinae

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MM 09 (Primary)
  • Indications Allergic rhinoconjunctivitis; Asthma; Hypersensitivity; Perennial allergic rhinitis
  • Focus Therapeutic Use
  • Acronyms MM09-SIT-023
  • Sponsors Inmunotek

    • Most Recent Events

    • 23 Mar 2022 Planned End Date changed from 1 Apr 2022 to 1 Dec 2025.
    • 23 Mar 2022 Planned primary completion date changed from 1 Jan 2022 to 1 Jan 2024.
    • 21 May 2021 Planned primary completion date changed from 1 Jan 2021 to 1 Jan 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top